Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
That's little money for a +400Mio Marketcap company. Any of these can also be put on leave without too much hassle. It is not bad news, but people are reading too much in this. One could assume they have received feedback... but well... assumptions...
From what I can read in the RNS, SNG never received the data from the Aktiv2 trial. If so, maybe we are reading too much in them opening job positions in the US (easy hire, easy fire), website update etc... They might just hope for a good phase3 outcome. Their moves might not be on actual preliminary insights of trial data. HAppy to stand corrected.
This is just a logical rerate... No need to speculate and break momentum when it does not materialize.
I have been wondering about that. If they give the same dose indeed, and little goes to waste in cells that are in the rest of the human body, more dox will be going around to attach to the actual tumor cells... But maybe it is not that simple. Maybe it gets secreted out via the kidneys?
Either way, if your theory is inline with reality, it would be a massive deal.. Less chemo required, way less toxicity and significant increase in efficacy.
I am reading confusing messages on the daily FCF for PMG. Dutch TTF pricing at 53EUR... Is this the price for a BOE? Or is that closer to a 100USD per BOE? Opex is about 9.9EUR(or USD?) per BOE... And that on about 800 BOE/day...
Thanks in advance for any clarification/correction...
At the end of the article it states:
"The study was funded by the Wellcome Trust, the Medical Research Council, the Technology Strategy Board and Avacta and is published today (30 June 2021) in the journal, Nature Communications."
So since it is partially funded by AVACTA, I presume they have at least partial rights to it.
I must be overlooking something, but where exactly is #avct beating @NanoReproAG with the antigen test?
https://www.m-medientechnik24.de/out/media/CPSR_Evaluation_NanoRepro_SARS-Cov-2%20Ag_Schnelltest_v02_MM24.pdf